OPKO Launches the 4Kscore Test in Mexico

OPKO Health, Inc. (NYSE: OPK) today announced the launch of the 4Kscore® test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S. and European launch of the 4Kscore test in 2014. The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1,012 patient blinded, prospective study in the United States in 2014. The results of this validation trial were published in the journal European Urology and presented at the 2014 Congress of the Mexican Society of Urology by one of the publication's authors, Dr. Sanoj Punnen, of the University of Miami. “We are pleased to now be able to offer the 4Kscore test to the clinicians and patients of Mexico,” said Joaquin Peniche, CEO of OPKO Health Mexico. “The plenary presentation on the 4Kscore was well received by Urologists attending the Congress of the Mexican Society of Urology in Guadalajara, Mexico this past November and we now look forward to offering the product into the Mexican market.” In Mexico, prostate cancer is the most common cause of cancer death in males with 5,911 deaths recorded in 2012.